At M3T, we're leading the development of novel treatments for neurological disease commonly associated with stroke and blood loss. M3T compounds reduce cell loss, systemic inflammation, and vascular damage seen during cerebral ischemia-reperfusion injury through modulation of Damaging Immune Cells, decreasing their deleterious effects at sites of hypoxia and trauma.
Damaging Immune Cells are now under our control
Mark L. Nelson, Ph.D.
Dr. Nelson has 30 years of drug discovery experience forming Paratek Pharmaceuticals (PRTK) and inventing the chemistry of the antibiotics Nuzyra ® and Seysara ® , FDA approved drugs for serious infections, dermatology, and bioterrorism protection. He received his Ph.D. at Temple University in Medicinal Chemistry and did his post-doctoral studies at Tufts University School of Medicine. His inventions and synthesis methods awarded him the 2019 American Chemical Society Heroes of Chemistry Award and he is a recognized authority on antibiotic chemistry, microbial pathogens, mitochondrial and molecular mechanisms of antibiotics against inflammation.
Marc W. Halterman, M.D., Ph.D.
Chief Science Officer, Co-Founder
Dr. Halterman is Professor & Chair of Neurology at the Stony Brook Renaissance School of Medicine. He received his BS in Chemistry from Georgetown University and MD/PhD training from the University of Rochester School of Medicine. He holds patents in gene therapy and drug discovery, and his lab is actively investigating the interplay between brain ischemia, systemic inflammation, and mechanisms driving delayed cerebrovascular injury following stroke and cardiac arrest.
Mark C. Grier, Ph.D.
Vice President-Chemistry, Co-Founder
Dr. Grier brings twenty plus years of experience in medicinal chemistry and drug discovery. Previously, he was Director of Medicinal Chemistry at Echelon Biosciences. Dr. Grier received a Ph.D. in synthetic organic chemistry from the University of Utah and received a B.S. in chemistry from Iowa State University. His accomplishments include over 25 patents and publications, and he was recently awarded the 2019 American Chemical Society Heroes of Chemistry Award for his contributions towards the development of Nuzyra ® and Seysara ® while at Paratek Pharmaceuticals.
Cynthia Ekberg Tsai
Cynthia Tsai is CEO of Healthquest, a global biotechnology advisory firm, and CEO of Tana Systems, providing strategy and business direction in technologies and strategic growth. A former Vice President at Merrill Lynch and Kidder Peabody, Ms. Tsai was founder and CEO of HealthExpo, a general partner at MassTech Ventures, and serves on the Boards of the Jefferson Foundation Awards and the Prix Galien Foundation. She earned a BA in Psychology from the University of Missouri, voted “Leading Woman Entrepreneur of the World, 2004” and brings to the company strategic and investment advice and public company building expertise.
Colonel (retired) Dallas C. Hack, MD MPH
Dr. Hack is a decorated Army veteran, a former Commander of NATO’s SHAPE Healthcare Facility, and a former Command Surgeon in Kuwait and Iraq during Operations Enduring Freedom and Iraqi Freedom. He was also Director of the Combat Casualty Care Research Program at the US Army Medical Research and Materiel Command, Fort Detrick, MD where he led over $2 billion in Trauma Research and Development funding (including brain health) across all Department of Defense groups. He earned a BA at Andrews University, a MD degree from Loma Linda University, and an MPH from Johns Hopkins University. Dr. Hack is advising the company on military and civilian medicine related to brain trauma and health, as well as clinical and regulatory strategies to develop neurological and chemotherapeutic interventions.
Copyright © 2022 M3 Therapeutics - All Rights Reserved.